GLP-1 Market
LLY $1427.28 ▼ -0.7% NVO $40.65 ▼ -1.1% PFE $28.83 ▼ -2.1% VKTX $27.58 ▼ -3.0% KLRA $13.21 ▼ -8.1% GPCR $19.84 ▼ -5.3% RHHBY $60.57 • 0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Mavorixafor

Company
X4 Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 13, 2026

Find a Clinical Trial Near Me

See recruiting studies for Mavorixafor and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06056297

    A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

    Not yet reported X4 Pharmaceuticals 176 participants Est. completion 2027-11 115 sites Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT00063804

    Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 44 participants Est. completion 2006-10 2 sites
    Other conditions: HIV Infections
    View official trial listing →
  • Completed NCT NCT00089466

    Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients

    Not yet reported, Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 6 participants Est. completion 2009-01 3 sites
    Other conditions: HIV Infections
    View official trial listing →
  • Completed NCT NCT00361101

    A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus

    Not yet reported Genzyme, a Sanofi Company 10 participants Est. completion 2010-04 2 sites
    Other conditions: HIV Infections, X4 Tropic Virus
    View official trial listing →
  • Completed NCT NCT02667886

    Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

    Not yet reported, Not yet reported X4 Pharmaceuticals 74 participants Est. completion 2022-04-14 20 sites Stand-alone
    Other conditions: Clear Cell Renal Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT02680782

    A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

    Not yet reported X4 Pharmaceuticals 15 participants Est. completion 2016-02-28 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02823405

    X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

    Not yet reported X4 Pharmaceuticals 16 participants Est. completion 2018-03-15 4 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Terminated NCT NCT02923531

    Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

    Not yet reported, Not yet reported X4 Pharmaceuticals 9 participants Est. completion 2018-08-08 4 sites Stand-alone
    Other conditions: Clear Cell Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT03005327

    A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

    Not yet reported X4 Pharmaceuticals 8 participants Est. completion 2022-06-16 2 sites Stand-alone
    Other conditions: WHIM Syndrome
    View official trial listing →
  • Completed NCT NCT03995108

    Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

    Not yet reported X4 Pharmaceuticals 31 participants Est. completion 2025-12-23 23 sites Stand-alone
    Other conditions: WHIM Syndrome
    View official trial listing →
  • Completed NCT NCT04154488

    A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

    Not yet reported, Not yet reported X4 Pharmaceuticals 32 participants Est. completion 2024-08-27 7 sites Stand-alone
    Other conditions: Neutropenia
    View official trial listing →
  • Completed NCT NCT04274738

    A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

    Not yet reported X4 Pharmaceuticals 16 participants Est. completion 2022-10-31 5 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Status unknown NCT NCT05103917

    A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

    Not yet reported, Not yet reported Abbisko Therapeutics Co, Ltd 24 participants Est. completion 2023-05-21 1 site Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT06858696

    A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

    Not yet reported X4 Pharmaceuticals 39 participants Est. completion 2026-01-12 4 sites Stand-alone
    Other conditions: Hepatic Insufficiency
    View official trial listing →
  • Completed NCT NCT06914869

    Drug-Drug Interaction Potential of Mavorixafor

    Not yet reported X4 Pharmaceuticals 38 participants Est. completion 2025-05-19 1 site Stand-alone
    Other conditions: Healthy Participants
    View official trial listing →
  • Not yet recruiting NCT NCT07902830

    A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders

    Not yet reported X4 Pharmaceuticals 40 participants Est. completion 2029-01-30 Stand-alone
    Other conditions: Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia, Autoimmune Neutropenia, Chronic Idiopathic Neutropenia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Mavorixafor, XOLREMDI, X4P-001

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.